Krystal Biotech (NASDAQ:KRYS) Earns Buy Rating from HC Wainwright

Krystal Biotech (NASDAQ:KRYS - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a research report issued on Wednesday,Benzinga reports. They currently have a $221.00 price target on the stock. HC Wainwright's price objective would suggest a potential upside of 41.09% from the stock's previous close.

A number of other equities analysts also recently weighed in on KRYS. William Blair raised shares of Krystal Biotech to a "strong-buy" rating in a research note on Friday, August 30th. Citigroup increased their target price on Krystal Biotech from $204.00 to $206.00 and gave the stock a "neutral" rating in a research note on Tuesday, November 5th. Stifel Nicolaus boosted their price objective on shares of Krystal Biotech from $204.00 to $220.00 and gave the stock a "buy" rating in a research report on Wednesday, September 11th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Krystal Biotech in a research note on Thursday, August 29th. Finally, Chardan Capital reaffirmed a "buy" rating and set a $212.00 price target on shares of Krystal Biotech in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Krystal Biotech presently has an average rating of "Buy" and an average price target of $206.67.

Krystal Biotech Stock Down 7.3 %

Krystal Biotech stock traded down $12.40 during mid-day trading on Wednesday, hitting $156.64. 359,642 shares of the company were exchanged, compared to its average volume of 322,707. Krystal Biotech has a 1-year low of $107.50 and a 1-year high of $219.34. The business has a fifty day moving average of $180.70 and a 200 day moving average of $185.17. The company has a market capitalization of $4.51 billion, a PE ratio of 88.50 and a beta of 0.80.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. The firm had revenue of $83.84 million for the quarter, compared to analysts' expectations of $82.94 million. During the same period in the prior year, the firm earned ($0.67) earnings per share. The company's quarterly revenue was up 879.9% compared to the same quarter last year. Research analysts expect that Krystal Biotech will post 2.97 earnings per share for the current year.

Insider Buying and Selling

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the firm's stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total value of $4,119,500.00. Following the sale, the insider now owns 1,475,882 shares of the company's stock, valued at $243,195,835.96. This trade represents a 1.67 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 14.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Franklin Resources Inc. grew its stake in Krystal Biotech by 34.2% in the third quarter. Franklin Resources Inc. now owns 243,760 shares of the company's stock worth $43,774,000 after purchasing an additional 62,178 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Krystal Biotech in the 3rd quarter worth about $40,000. Teachers Retirement System of The State of Kentucky lifted its position in Krystal Biotech by 198.2% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 9,010 shares of the company's stock valued at $1,640,000 after acquiring an additional 5,989 shares during the period. Geode Capital Management LLC boosted its stake in Krystal Biotech by 2.0% during the third quarter. Geode Capital Management LLC now owns 591,631 shares of the company's stock worth $107,714,000 after acquiring an additional 11,411 shares in the last quarter. Finally, Main Management ETF Advisors LLC purchased a new stake in Krystal Biotech in the third quarter worth about $706,000. 86.29% of the stock is owned by hedge funds and other institutional investors.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).